Bookbuilding IPO | ₹200 Cr | Listed at BSE, NSE | Mon, Jun 14, 2010 - Thu, Jun 17, 2010
Parabolic Drugs IPO is a book build issue of ₹200.00 crores. The issue is a combination of fresh issue of 2.46 crore shares aggregating to ₹184.81 crores and offer for sale of 0.20 crore shares aggregating to ₹15.19 crores.
Parabolic Drugs IPO bidding started from Jun 14, 2010 and ended on Jun 17, 2010. The shares got listed on BSE, NSE on Jul 1, 2010.
Parabolic Drugs IPO price band is set at ₹75 per share. The lot size for an application is 80. The minimum amount of investment required by an retail is ₹6,800 (80 shares) (based on upper price). The lot size investment for sNII is 34 lots (2,720 shares), amounting to ₹2,04,000, and for bNII, it is 167 lots (13,360 shares), amounting to ₹10,02,000.
The issue includes a reservation of up to 5,00,000 shares for employees offered at a discount of ₹0.00 to the issue price.
ICICI Securities Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Parabolic Drugs IPO RHP for detailed Information.
IPO Open
Mon, Jun 14, 2010
IPO Close
Thu, Jun 17, 2010
Issue Price
₹75 per share
Market Cap (Pre-IPO)
₹464.19 Cr
| IPO Date | 14 to 17 Jun, 2010 |
| Listed on | Thu, Jul 1, 2010 |
| Face Value | ₹10 per share |
| Price Band | ₹75 to ₹85 |
| Issue Price | ₹75 per share |
| Lot Size | 80 Shares |
| Sale Type | Fresh capital cum OFS |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Total Issue Size | 2,66,66,667 shares (agg. up to ₹200 Cr) |
| Fresh Issue | 2,46,40,965 shares (agg. up to ₹185 Cr) |
| Offer for Sale | 20,25,702 shares of ₹10 (agg. up to ₹15 Cr) |
| Share Holding Pre Issue | 3,72,51,049 shares |
| Share Holding Post Issue | 6,18,92,014 shares |
| BSE Script Code / NSE Symbol | 533211 / PARABDRUGS |
| ISIN | INE618H01016 |
Parabolic Drugs IPO comprises a total issue size of 2,66,66,667 shares. The net offer to the public is 2,61,66,667 shares, after excluding 5,00,000 shares under a preferential allotment. Of the Net offer 1,30,83,333 (50.00%) are allocated to QIB, 39,25,000 (15.00%) allocated to NII 91,58,334 (35.00%) allocated to RII.
| Investor Category | Shares Offered | % of Net Issue | % of Total Issue | Max Allottees |
|---|---|---|---|---|
| QIB Shares Offered | 1,30,83,333 | 50.00% | 49.06% | NA |
| NII (HNI) Shares Offered | 39,25,000 | 15.00% | 14.72% | NA |
| Retail Shares Offered | 91,58,334 | 35.00% | 34.34% | 1,14,479 |
| Preferential Reservations | ||||
| Employee Shares Offered | 5,00,000 | 1.87% | NA | |
| Total Shares Offered | 2,66,66,667 | 100.00% | 100.00% | |
Investors can bid for a minimum of 80 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 80 | ₹6,000 |
| Retail (Max) | 33 | 2,640 | ₹1,98,000 |
| S-HNI (Min) | 34 | 2,720 | ₹2,04,000 |
| S-HNI (Max) | 166 | 13,280 | ₹9,96,000 |
| B-HNI (Min) | 167 | 13,360 | ₹10,02,000 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 1996, Parabolic Drugs Limited is in the business of manufacturing Active Pharmaceutical Ingredients (API's) and API intermediates. APIs, also known as 'bulk drugs' or 'bulk actives' are the principal ingredient used in making finished dosages in the form of capsules, tablets, liquid, or other forms of dosage, with the addition of other APIs or inactive ingredients.
Companies product portfolio comprises 42 APIs and 7 API intermediates which are marketed domestically and exported.
Company own and operate two manufacturing facilities at Derabassi, Punjab, and Panchkula, Haryana. Company is in the process of setting up a custom synthesis and research and development (R&D) center at Barwala, Haryana.
| Period Ended |
|---|
| Amount in ₹ Crore |
The Company proposes to utilise the Net Proceeds from the Issue towards the following objects:
| # | Issue Objects | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Multi-purpose block III at Derabassi | 20.32 |
| 2 | Sterile cephalosporin plant at Derabassi | 32.55 |
| 3 | Establishment of Chachrauli plant | 16.04 |
| 4 | Investment in our Subsidiary; | 46.62 |
| 5 | Repayment / prepayment of identified loan facilities | 38.84 |
| 6 | General corporate purposes | 17.59 |
| Pre IPO | Post IPO | |
|---|---|---|
| Promoter Holding | 63.21% | 38.04% |
| Market Cap | ₹464.19 Cr. |
The Parabolic Drugs IPO is subscribed 1.04 times on June 17, 2010 5:00:00 PM (Day 3). The public issue subscribed 0.4 times in the retail category, 1.48 times in the QIB category, and 1.2 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 1.48 | 1,30,83,333 | |
| NII | 1.2 | 39,25,000 | |
| Retail | 0.4 | 91,58,334 | |
| Employee | 0.11 | 5,00,000 | |
| Total | 1.04 | 2,66,66,667 |
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Lead management fees | 6.40 |
| 2 | Underwriting and selling commission (including commission to SCSBs for ASBA Applications) | 2.05 |
| 3 | Registrar‘s fees | 0.09 |
| 4 | Advertisement and marketing expenses | 1.09 |
| 5 | Printing and distribution expenses | 1.72 |
| 6 | IPO Grading expenses | 0.11 |
| 7 | Advisors | 0.70 |
| 8 | Bankers to the Issue | |
| 9 | Others (SEBI filing fees, bidding software expenses, depository charges, listing fees, etc.) | 1.74 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹75.00 | ₹75.00 |
| Open | ₹76.00 | ₹75.00 |
| Low | ₹63.00 | ₹63.10 |
| High | ₹79.00 | ₹75.95 |
| Last Trade | ₹64.80 | ₹64.85 |
Lead Manager Reports
Parabolic Drugs IPO is a main-board IPO of 2,66,66,667 equity shares of the face value of ₹10 aggregating up to ₹200 Crores. The issue is priced at ₹75 per share. The minimum order quantity is 80.
The IPO opens on Mon, Jun 14, 2010, and closes on Thu, Jun 17, 2010.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Parabolic Drugs IPO using UPI as a payment gateway. Zerodha customers can apply in Parabolic Drugs IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Parabolic Drugs IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Parabolic Drugs IPO opens on Mon, Jun 14, 2010 and closes on Thu, Jun 17, 2010.
Parabolic Drugs IPO lot size is 80, and the minimum amount required for application is ₹6,000.
You can apply in Parabolic Drugs IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Parabolic Drugs IPO will be done on [.], and the allotted shares will be credited to your demat account by . Check the Parabolic Drugs IPO allotment status.
The Parabolic Drugs IPO listing date is on Thu, Jul 1, 2010.
